Cytosorbents (CTSO) Net Cash Flow (2010 - 2026)

Cytosorbents (CTSO) has reported Net Cash Flow for 17 consecutive years, with -$576000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Cash Flow rose 64.9% year-over-year to -$576000.0; the trailing twelve-month figure through Jun 2026 stood at -$6.9 million (down 99.43% YoY), and the FY2025 full-year result was -$3.5 million, up 39.59% from the prior year.
• Net Cash Flow improved to -$576000.0 in Q2 2026 per CTSO's latest filing, from -$1.2 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $5.7 million in Q4 2023 and bottomed at -$12.7 million in Q2 2022.
• Historically, Net Cash Flow has averaged -$2.7 million across 5 years, with a median of -$2.6 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Net Cash Flow slumped 340.15% in 2022, then surged 1137.17% in 2023.
• Over 5 years, Net Cash Flow stood at -$546406.0 in 2022, then soared by 1137.17% to $5.7 million in 2023, then sank by 140.55% to -$2.3 million in 2024, then fell by 14.8% to -$2.6 million in 2025, then jumped by 78.17% to -$576000.0 in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$576000.0, -$1.2 million, and -$2.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.